Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors
about
Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOPPeptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agentsDiscovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptorsThe nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medicationsNociceptin produces antinociception after spinal administration in amphibiansStructure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphineC7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.Activities of mixed NOP and mu-opioid receptor ligands.Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors.Development of nociceptin receptor (NOP) agonists and antagonists.Recently patented and promising ORL-1 ligands: where have we been and where are we going?Pharmacokinetics of non-intravenous formulations of fentanyl.Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.Buprenorphine for neuropathic pain--targeting hyperalgesia.Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.A novel and selective nociceptin receptor (NOP) agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) decreases acquisition of ethanol-induced conditioned place preference in mice.
P2860
Q24647921-63496C32-1191-4F8A-8E32-78CF9F6D4B05Q28178485-329E9F5A-9BC2-4837-A8F3-CDF0A9C79CECQ28256196-1911C6A2-4F2C-4D45-AE27-9CFB58EF472FQ28297686-C1FAEA56-943B-45E0-A0C3-9E9DF98A424EQ28754925-3129152C-977F-4964-9623-AE9A1AFFC14CQ34408300-53212C94-7C47-4F67-B363-15BEC97D41CAQ35284997-826F2DCB-34AB-4EF9-93A1-F9255BE24656Q35669185-DD811361-FCD7-40DC-BF62-9F0EB1BFAE00Q36087159-E6FCF067-4A26-4E24-A41B-3C9B0A340FE4Q36296864-983EE427-BA77-45DA-8A78-A4682C36D21DQ36456876-D55E5CF9-CA7E-4D91-86C6-EC73470BC1C1Q36508649-6F5BD9A3-9B9D-4F53-B762-D79CE7F49EB5Q37680813-BA8D5F54-7D2E-4D45-A698-FC98BB3EC3C7Q37697788-DC7950C5-C2D6-4CBA-BCE0-76AEFD58700CQ38055713-84B914BC-5DCD-4102-AA17-C4179CF048FFQ40227077-0B7CC033-B4CE-4A32-91D0-A48809B000BCQ41134315-AA50CA94-A2CF-4025-AABF-3CD86497050DQ42378885-E49CB17C-7CCC-4768-8151-3E28C3F02DF9Q42699426-71C3F989-BFDE-4468-BA63-376F31FABAB4Q42703424-5554597C-9B66-4B7D-AD8E-8D3D85B82BC7Q43295219-4D909D7D-4EE7-4BD0-A15D-1D4B9D4310F3Q44350300-1D65DDF6-7650-45E8-A640-3A350ACD7BCFQ46101192-CA24A576-58E9-49F9-B040-9BF4E7AE97A6
P2860
Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@ast
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@en
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@nl
type
label
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@ast
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@en
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@nl
prefLabel
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@ast
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@en
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@nl
P2093
P2860
P1476
Characterization of opiates, n ...... s at ORL1 and opioid receptors
@en
P2093
A B Kelson
W E Polgar
P2860
P356
10.1016/S0014-2999(01)01282-1
P407
P577
2001-09-28T00:00:00Z